3-Allyl-hydantoinsaeure | 3366-94-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Allyl-hydantoinsaeure
• 英文别名: Glycine, N-allyl-N-carbamoyl-；2-[carbamoyl(prop-2-enyl)amino]acetic acid
• CAS: 3366-94-7
• 化学式: C₆H₁₀N₂O₃
• 分子量: 158.157
• InChiKey: SOPNXJIUIXPRAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  potassium cyanate 、 烯丙基氨基乙酸盐酸盐 以 水 为溶剂， 生成 3-Allyl-hydantoinsaeure
  参考文献：
  名称：

  烯丙二醛的汞衍生物。

  摘要：

  DOI：

  10.1021/jm01236a015

文献信息

• Mercapto-acylamino acid antihypertensives
  申请人：SCHERING CORPORATION

  公开号：EP0355784A1

  公开（公告）日：1990-02-28

  Mercapto-acylamino acids of the formula: wherein n is 0-4; R is R₁ is 1-3 substituents selected from the group consisting of hydrogen, halogeno, lower alkyl, cyclolower alkyl, lower alkoxy, hydroxy, aryl, aryloxy, cyano, aminomethyl, carboxy, lower alkoxy carbonyl and carbamyl; R₂ is hydrogen, R₁₁-- or R₁₁--OCH₂-, wherein R₁₁ is lower alkyl, aryl or arylmethyl; R³ is -OR₁₂, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ are independently lower alkyl, aryl lower alkyl, (cyclolower alkyl) lower alkyl, substituted aryl lower alkyl or substituted (cyclolower alkyl) lower alkyl, wherein in the substituents on the aryl and cyclolower alkyl portions are 1-3 substituents selected from the group consisting of lower alkyl, hydroxy, halogeno, lower alkoxy and amino, or R₄ and R₅ are alkyl and together with the sulfur and carbon atoms to which they are attached form a 5-7 membered ring; R₁₂ and R₁₃ are independently hydrogen, lower alkyl or substituted lower alkyl wherein the substituents are selected from the group consisting of 1 or 2 hydroxy groups, 1 or 2 lower alkoxy groups, lower alkoxy lower alkoxy, halogeno, halogeno lower alkoxy, amino, mono- or di-lower alkylamino, aryl, substituted aryl wherein the substituents on aryl are 1-3 substituents selected from the group consisting of lower alkyl, hydroxy, halogeno, lower alkoxy and amino, and a 5-6 membered saturated ring comprising 1-2 oxygen atoms as ring members wherein the ring carbon atoms can be substituted with 0-2 lower alkyl substituents; or R₁₂ and R₁₃ together with the nitrogen to which they are attached complete a 5-7 membered ring, wherein one of the 4-6 ring members comprising R₁₂ and R₁₃ may be a nitrogen atom, an alkyl-substituted nitrogen atom or an oxygen atom, and wherein the ring may be substituted on the ring carbon atoms with substituents chosen from alkyl and hydroxy groups; R₁₄ is hydrogen, alkyl, carboxyalkyl, mercaptoalkyl, alkylthioalkyl, aminoalkyl, hydroxyalkyl, phenylalkyl, hydroxyphenylalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl or carbamoylalkyl; the pharmaceutically acceptable salts thereof and their combinations with atrial natriuretic factors or angiotensin converting enzyme inhibitors are disclosed. Such preparations are useful for treating hypertension and congestive heart failure.

  公式为：其中n为0-4；R为R₁为从氢，卤代，低烷基，环低烷基，低烷氧基，羟基，芳基，芳基氧基，氰基，氨甲基，羧基，低烷氧羰基和氨基甲酰中选择的1-3个取代基；R₂为氢，R₁₁-或R₁₁-OCH₂-，其中R₁₁为低烷基，芳基或芳基甲基；R³为-OR₁₂，R₄、R₅、R₆、R₇、R₈、R₉和R₁₀分别为独立的低烷基，芳基低烷基，（环低烷基）低烷基，取代芳基低烷基或取代（环低烷基）低烷基，其中在芳基和环低烷基部分的取代基是从低烷基，羟基，卤代，低烷氧基和氨基中选择的1-3个取代基，或R₄和R₅为烷基，并与它们附着的硫和碳原子一起形成一个5-7成员环；R₁₂和R₁₃分别为氢，低烷基或取代低烷基，其中取代基是从1或2个羟基，1或2个低烷氧基，低烷氧基低烷氧基，卤代，卤代低烷氧基，氨基，单烷基或双烷基氨基，芳基，取代芳基中选择的取代基是从低烷基，羟基，卤代，低烷氧基和氨基中选择的1-3个取代基，以及包含1-2个氧原子作为环成员的5-6成员饱和环，其中环碳原子可以用0-2个低烷基取代基取代；或R₁₂和R₁₃与它们附着的氮一起形成一个5-7成员环，其中4-6个环成员之一包括R₁₂和R₁₃可以是氮原子，烷基取代的氮原子或氧原子，并且环上的环碳原子可以用从烷基和羟基中选择的取代基取代；R₁₄为氢，烷基，羧基烷基，巯基烷基，硫代烷基，氨基烷基，羟基烷基，苯基烷基，羟基苯基烷基，鸟氨酸基烷基，咪唑基烷基，吲哚基烷基或氨甲酰基烷基；公开了其药学上可接受的盐及其与心房利钠肽因子或血管紧张素转化酶抑制剂的组合。这样的制剂对治疗高血压和充血性心力衰竭有用。
• [EN] TREATING INCREASED INTRAOCULAR PRESSURE CAUSED BY STEROIDS
  申请人：SCHERING CORPORATION

  公开号：WO1987002585A2

  公开（公告）日：1987-05-07

  (EN) The rise in intraocular pressure associated with the use of steroidal anti-inflammatory drugs is controlled by use of angiotensin converting enzyme inhibitors. For the purposes of the invention, the preferred ACE inhibitor is 7-¨ADN-(1(S)-carboxy-3-phenylpropyl)-(S)-alanyl¨BD-1,4-dithia-7-azaspiro¨AD4.4¨BDnonane-8(S)-carboxylic acid.(FR) L'augmentation de la pression intra-oculaire associée à l'utilisation de médicaments stéroïdes anti-inflammatoires est contrôlée en utilisant des inhibiteurs d'une enzyme de conversion de l'angiotensine. Selon l'invention, l'inhibiteur préféré d'une enzyme de conversion de l'angiotensine est l'acide 7-¨ADN-(1(S)-carboxy-3-phénylpropyl)-(S)-alanyl¨BD-1,4-dithia-7-azaspiro¨AD4.4¨BDnonane-8(S)-carboxylique.

  使用类固醇类抗炎药物会导致眼内压力升高，但使用血管紧张素转换酶抑制剂可以控制。在本发明中，首选的血管紧张素转换酶抑制剂是7-¨ADN-(1(S)-羧基-3-苯基丙基)-(S)-丙氨酰¨BD-1,4-二硫-7-氮杂螺¨AD4.4¨BD-壬烷-8(S)-羧酸。
• Neutral metalloendopeptidase inhibitors in the treatment of hypertension
  申请人：SCHERING CORPORATION

  公开号：EP0254032A2

  公开（公告）日：1988-01-27

  The method of treating hypertension with neutral metalloendopeptidase (NMEP) inhibitors, NMEP inhibitors in combination with atrial peptides, and NMEP inhibitors in combination with angiotensin converting enzyme inhibitors, as well as pharmaceutical compositions therefor, are disclosed.

  本研究公开了使用中性金属内肽酶（NMEP）抑制剂、NMEP 抑制剂与心房肽联合使用、NMEP 抑制剂与血管紧张素转换酶抑制剂联合使用治疗高血压的方法及其药物组合物。
• Mercapto-acylamino acids useful in the treatment of cardiovascular disorders and as analgesics
  申请人：SCHERING CORPORATION

  公开号：EP0364767A1

  公开（公告）日：1990-04-25

  Novel mercapto-acylamino acids of formula I wherein R₁ is H or R₅CO-; R₂ is Y-C₆H₄-, Y-C₆H₄S-, Y-C₆H₄O-, Y-C₆H₄CH₂S-, Y-C₆H₄CH₂O-, naphthyl, furyl, thienyl, benzofuryl, benzothienyl, diphenylmethyl or R₃ is -OR₆, -NR₆R₇ or R₄ is hydrogen, lower alkyl or aryl lower alkyl; R₅ is lower alkyl, hydroxylower alkyl, lower alkoxy lower alkyl; (di-lower alkyl) amino lower alkyl, Y₁-C₆H₄-lower alkyl, lower alkoxy, Y₁-C₆H₄-, naphthyl, furyl, thienyl or pyridyl; R₆ and R₇ are independently hydrogen, lower alkyl or substituted lower alkyl wherein the substituents are hydroxy, lower alkoxy, lower alkoxy lower alkoxy, halogeno, halogeno lower alkoxy, amino, mono- or di-lower alkylamino, heterocycloalkyl, lower alkyl heterocycloalkyl, aryl, substituted aryl or an optionally substituted 5-6 membered saturated ring comprising 1-2 oxygen atoms as ring members; or R₆ and R₇ together with the nitrogen to which they are attached complete a 5-7 membered ring, wherein the ring optionally comprises a nitrogen atom, an alkyl-substituted nitrogen atom or an oxygen atom, and wherein the ring is optionally substituted on the ring carbon atoms; R₈ is hydrogen, alkyl, carboxyalkyl, mercaptoalkyl, alkylthioalkyl, aminoalkyl, hydroxyalkyl, phenylalkyl, hydroxyphenylalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl or carbamoylalkyl; n is 0-3; A is X and X₁ are a bond, -O-, -S-, or -CH₂-; Y, Y₁ and Y₂ are hydrogen, lower alkyl, cyclolower alkyl, lower alkoxy, OH, F, Cl, Br, I, -CN, -CO₂H, -CO₂-lower alkyl, -CH₂NH₂, -CONH₂ or aryl; and the pharmaceutically acceptable acid addition salts thereof useful as analgesics as well as in the treatment of hypertension and congestive heart failure and combinations of mercapto acylamino acids and atrial natriuretic factors or angiotensin converting enzyme inhibitors useful for treating hypertension and congestive heart failure are disclosed.

  式 I 的新型巯基乙酰胺酸 其中 R₁ 是 H 或 R₅CO-； R₂ 是 Y-C₆H₄-、Y-C₆H₄S-、Y-C₆H₄O-、Y-C₆H₄CH₂S-、Y-C₆H₄CH₂O-、萘基、呋喃基、噻吩基、苯并呋喃基、苯并噻吩基、二苯基甲基或 R₃ 是-OR₆、-NR₆R₇ 或 R₄ 是氢、低级烷基或芳基低级烷基； R₅ 是低级烷基、羟基低级烷基、低级烷氧基低级烷基；（二低级烷基）氨基低级烷基、Y₁-C₆H₄-低级烷基、低级烷氧基、Y₁-C₆H₄-、萘基、呋喃基、噻吩基或吡啶基； R₆ 和 R₇ 独立地为氢、低级烷基或取代的低级烷基，其中取代基为羟基、低级烷氧基、低级烷氧基低级烷氧基、卤代、卤代低级烷氧基、氨基、单或双低级烷基氨基、杂环烷基、低级烷基杂环烷基、芳基、取代的芳基或由 1-2 个氧原子作为环成员组成的任选取代的 5-6 位饱和环；或 R₆ 和 R₇ 与它们所连接的氮一起组成一个 5-7 个成员的环，其中该环任选包括一个氮原子、一个烷基取代的氮原子或一个氧原子，并且该环在环碳原子上任选被取代； R₈ 是氢、烷基、羧基烷基、巯基烷基、烷硫基烷基、氨基烷基、羟基烷基、苯基烷基、羟苯基烷基、胍基烷基、咪唑基烷基、吲哚基烷基或氨基甲酰基烷基； n 为 0-3； A 是 X 和 X₁ 是键、-O-、-S- 或 -CH₂-； Y、Y₁ 和 Y₂ 是氢、低级烷基、环低级烷基、低级烷氧基、OH、F、Cl、Br、I、-CN、-CO₂H、-CO₂-低级烷基、-CH₂NH₂、-CONH₂ 或芳基； 本发明公开了可用作镇痛剂以及治疗高血压和充血性心力衰竭的巯基乙酰氨基酸及其药学上可接受的酸加成盐，以及可用于治疗高血压和充血性心力衰竭的巯基乙酰氨基酸与心房利钠因子或血管紧张素转换酶抑制剂的组合。
• ANTIGLAUCOMA COMPOSITIONS
  申请人：SCHERING CORPORATION

  公开号：EP0227818A1

  公开（公告）日：1987-07-08